Antonio Ocampo Hermida

Statistics

Publications

Citations

516

H-Index

Active since

2018

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

ViiV Healthcare (United Kingdom)

Antonio Ocampo Hermida is an author at GlaxoSmithKline (United Kingdom) specializing in antiviral agents, antiretroviral response, and infectious disease pharmacotherapy.

Publications per year

2018–2021

Publications

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 135 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

1–2 of 2